Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
2.410
0.00 (0.00%)
Apr 21, 2025, 4:00 PM EDT - Market closed

Company Description

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers.

The company’s proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer.

Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors.

The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery.

It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop DNase technology for the treatment of immunotherapies.

The company offers under XDNASE, XCART, OncoHist, PolyXen, ErepoXen, and ImuXen trandemarks. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Xenetic Biosciences, Inc.
Xenetic Biosciences logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 2
CEO James Parslow

Contact Details

Address:
945 Concord Street
Framingham, Massachusetts 01701
United States
Phone 781 778 7720
Website xeneticbio.com

Stock Details

Ticker Symbol XBIO
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001534525
CUSIP Number 984015503
ISIN Number US9840156023
Employer ID 45-2952962
SIC Code 2834

Key Executives

Name Position
James F. Parslow Chief Financial Officer, Chief Operating Officer, Interim Chief Executive Officer and Corporate Secretary

Latest SEC Filings

Date Type Title
Apr 10, 2025 8-K Current Report
Mar 19, 2025 8-K/A [Amend] Current report
Mar 19, 2025 8-K Current Report
Mar 18, 2025 10-K Annual Report
Dec 13, 2024 8-K Current Report
Nov 13, 2024 8-K Current Report
Nov 12, 2024 10-Q Quarterly Report
Nov 7, 2024 8-K Current Report
Nov 1, 2024 EFFECT Notice of Effectiveness
Oct 31, 2024 8-K Current Report